MET and hereditary clear cell renal cell carcinoma: As a multi-targeting tyrosine kinase inhibitor, 20 also inhibits VEGFR2 and other kinases such as RET and AXL, and has been primarily used for the treatment of renal cell carcinoma and liver cancers.66 Further generations of cMET inhibitor have been developed, with capmatinib being the first selective cMET tyrosine kinase inhibitor approved, for resistant non-small cell lung cancer.65